Well, sort of. According to reports, KaloBios Pharmaceuticals has reportedly filed for Chapter 11 bankruptcy listing more than $1.9m in debt and more than $8.1m in assets. Trouble for the company is mounting, considering, Nasdaq informed the company that because of Shrkeli’s deceit on the stock market — they would be delisted come 25 December.